Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA
- 1 January 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 86 (1) , 106-111
- https://doi.org/10.1111/j.1365-2141.1994.tb03259.x
Abstract
We have established an ELISA for detecting thrombin cleavage of the FVIII light chain at Arg1689. The method used a coating alloantibody which recognized amino acid residues 2248-2312 in the C2 domain, together with a second monoclonal antibody, NMC-VIII/10, which recognized residues 1675-1684 in the amino-terminal region of the light chain. FVIII antigen (FVIII:Ag) was measured after treatment of plasma with various concentrations of thrombin. The FVIII:Ag of normal plasma was reduced in a dose-dependent manner by the thrombin, falling to 28% in the presence of 100 U/ml enzyme. The concentration of thrombin that achieved 50% reduction (IC50) was approximately 1.0 U/ml. The plasma of four haemophilia A positive (A+) and two haemophilia A reduced (AR) patients were analysed. The IC50 of all patients was more than 1.0 U/ml, indicating that thrombin cleavage of the FVIII light chain was defective. One haemophilia A+ plasma did not respond to thrombin in this ELISA system. The patient (TI) was a haemophiliac with FVIII coagulant activity of 0.04 U/ml and FVIII:Ag of 1.78 U/ml. In addition, immunoblotting of the purified FVIII from TI showed that thrombin cleavage of the 80 kilodalton (kD) light chain was impaired. The patient's DNA was amplified using the polymerase chain reaction with a set of synthetic oligonucleotide primers spanning amino acid residues 1646-1714. Sequence analysis of the amplified DNA fragments revealed a cytosine to thymine transition, converting an arginine 1689 to cysteine. This abnormal FVIII was designated as FVIII Hiroshima. Our ELISA system is a simple and useful method of evaluating the proteolytic cleavage by thrombin at Arg1689.Keywords
This publication has 30 references indexed in Scilit:
- A monoclonal antibody (NMC‐VIII/10) to factor VIII light chain recognizing Glu1675–Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cellsBritish Journal of Haematology, 1992
- Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.Journal of Clinical Investigation, 1992
- Factor VIII polypeptide specificity of monoclonal anti-factor VIII antibodiesBritish Journal of Haematology, 1988
- Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell AnemiaScience, 1985
- Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.Journal of Clinical Investigation, 1985
- Molecular cloning of a cDNA encoding human antihaemophilic factorNature, 1984
- Structure of human factor VIIINature, 1984
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984
- An Immunoradiometric Assay for Procoagulant Factor VIII Antigen: Results in Haemophilia, von Willebrand's Disease and Fetal Plasma and SerumBritish Journal of Haematology, 1979
- Hemophilia A: Polymorphism Detectable by a Factor VIII AntibodyScience, 1969